Industry revenue was only up 4%, according to Ernst & Young’s annual Pulse of the Industry report.
The market is projected to hit nearly $4.2 billion by 2025.
The Wall Street Journal reports that the scandal-ridden company will dissolve after failing to sell itself, and investors will lose nearly $1 billion.
Following protocols and maintaining compliance have been common themes.
MRI-compatible pacemakers are among the technologies gaining traction.
Research and development activities to find potential treatments using next generation sequencing for various fatal conditions including melanoma, epilepsy, antibody deficiency, and other diseases have gained traction. In April, FDA finalized two guidance documents to speed up development of NGS-based tests.
The increase is significantly less than FY 2018, which saw user fees go up 33%.
The vote is a step towards getting rid of the tax for good.
Before accepting money, the following is a guide to your due diligence process.
Timothy Scannell will take on the new role effective August 1.